Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Details : MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor, that demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being investigated for treatment of symptomatic obstructive HCM which is a progressive disease that thickens heart walls and makes it harder for the heart to expand normally and...
Product Name : Camzyos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA submission was based on the results of the pivotal Phase 3 EXPLORER-HCM trial, which evaluated mavacamten in patients with symptomatic oHCM versus placebo.
Product Name : Camzyos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2021
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : BofA Securities
Deal Size : Undisclosed
Deal Type : Public Offering
MyoKardia Announces Pricing of Public Offering of Common Stock
Details : The net proceeds support MyoKardia's planned regulatory approval process and commercial launch of mavacamten, if approved to fund ongoing and later-stage clinical studies of mavacamten in non-obstructive HCM, danicamtiv and MYK-224 in the area of Cardiov...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : BofA Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition
Details : Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $13,100.0 million
November 17, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $13,100.0 million
Deal Type : Acquisition
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten
Details : Mavacamten treatment resulted in favorable effect on cardiac structure -- significantly reduced hypertrophy in patients with hypertrophic cardiomyopathy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : American College of Cardiology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : MyoKardia and American College of Cardiology reported establishment of a nationwide registry of hypertrophic cardiomyopathy. The registry will support MyoKardia’s post-marketing safety and effectiveness study of mavacamten.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : American College of Cardiology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : LianBio
Deal Size : $187.0 million
Deal Type : Collaboration
Details : The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : LianBio
Deal Size : $187.0 million
Deal Type : Collaboration
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MyoKardia's Mavacamten Met Primary and Secondary Endpoints in Phase 3 EXPLORER Clinical Trial
Details : Mavacamten demonstrated a robust treatment effect: the primary and all secondary endpoints of the EXPLORER trial were met with statistical significance (p≤0.0006 for all endpoints).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the pivotal Phase 3 clinical trial of patients with symptomatic, obstructive hypertrophic cardiomyopathy will form the foundation of the company’s NDA for mavacamten, which MyoKardia intends to submit in the first quarter of 2021.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : Mavacamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable